Ponstan

Click "What site?" for further details.

Sites with a red asterisk (*) by them may be temporarily unavailable.
Sites with a black asterisk (*) by them may require a prior prescription.

Dosage Site Product Price Shipping Price Total Price   90 Capsules, 250mg (Generic) * *What site?     $41.65 $15.00 $56.65 250 Mg (mefenamic) 100 Caps *What site?   $58.00 $15.00 $73.00 250 MG (CAP) *What site?   $72.02 $13.40 $85.42 250MG, 100 dose * *What site?     $80.90 $11.95 $92.85

Ponstan has analgesic, anti-inflammatory and anti-pyretic properties for the treatment of post traumatic conditions such as pain, swelling and inflammation, for a maximum period of 5 days.

Contra-Indications
Sensitivity to mefenamic acid and other nonsteroidal anti-inflammatory agents with prostaglandin-synthetase inhibiting activity. Because the possibility exists for cross-sensitivity among nonsteroidal anti-inflammatory agents, Ponstan should not be given to patients in whom these drugs induce symptoms of bronchospasm, allergic rhinitis, or urticaria.
Ponstan is contra-indicated in patients with chronic inflammation of either the upper or lower gastro-intestinal tract, in patients with a history of peptic and/or intestinal ulceration, patients with impaired renal or hepatic function, and epileptics.
Safety in pregnancy and lactation has not yet been established.

Warning
If diarrhoea or skin rash appear, Ponstan should be discontinued immediately.

Dosage and Directions for Use
Therapy should not be continued for longer than 7 days.
Adults: 500 mg three times per day.
In menorrhagia the dosage is 500 mg three times a day beginning with the onset of menstrual flow and continuing for five days or until cessation of flow, whichever is less.
In primary dysmenorrhoea the dosage is 500 mg three times a day commencing at the onset of period pain and continued for up to three days while the symptoms persist.
Children (6 months and older): 25 mg/kg of body weight daily, in divided doses, or:
6 months to 1 year: One medicine measureful (5 mL).
2 to 4 years: Two medicine measuresful (10 mL).
5 to 8 years: Three medicine measuresful (15 mL).
9 to 12 years: Four medicine measuresful (20 mL).
The dose may be repeated as necessary, up to three times daily.
Gastric irritation may be reduced by taking medication during meals.
Paediatric Suppositories:
Children 6 months to 2 years, weighing not less than 10 kg: One suppository to be inserted rectally three times a day at intervals of 6 to 8 hours as needed.
One 125 mg suppository is equivalent to approximately 60 mg (6 mL) Ponstan suspension.
The use of paediatric suppositories every 6 to 8 hours for longer than 24 hours is not recommended.

Side-Effects and Special Precautions
Side-effects:
The most frequently reported side-effects were gastro-intestinal disturbances, and include: diarrhoea, nausea with or without vomiting and abdominal pain.
Diarrhoea may occur within 24 hours following usual analgesic dosage. When diarrhoea occurs, the medication should be discontinued immediately. Temporary lowering of the white blood cell count has occurred but does not appear to be dose-related. Blood counts should be performed at regular intervals during long-term administration.
Serious gastro-intestinal toxicity such as bleeding, ulceration, and perforation can occur at any time with or without warning symptoms, in patients treated chronically with nonsteroidal anti-inflammatory agents. Elderly or debilitated patients seem unable to tolerate ulceration or bleeding as well as some other individuals; most spontaneous reports of gastro-intestinal events are in this population.
Less frequently reported gastrointestinal side effects include: anorexia, pyrosis, flatulence, enterocolitis, colitis, steatorrhoea, cholestatic jaundice, hepatitis, pancreatitis, hepatorenal syndrome, mild hepatic toxicity, constipation and peptic ulceration with and without gastro-intestinal haemorrhage.
Headache, drowsiness, dizziness, nervousness, convulsions, insomnia, visual disturbances and ear pain have been reported.
Other side-effects which may occur are, hypotension, asthma, glucose intolerance in diabetic patients, palpitations and dyspnea.
Haemolytic anaemia may develop in patients taking Ponstan continuously for extended periods. While this condition is generally reversible, death due to Ponstan-associated haemolytic anaemia has been reported. Liver function tests must be carried out regularly to monitor elevation of enzymes and bilirubin.
Other reported haematological effects include agranulocytosis, decreased hematocrit, leukopenia, eosinophilia, aplastic anaemia, pancytopenia, thrombocytopenia or thrombocytopenic purpura and bone marrow aplasia.
Acute hypersensitivity reactions (urticaria, bronchospasm, anaphylaxis) have occurred. Because of the possibility of cross-sensitivity due to structural relationships which exist among nonsteroidal anti-inflammatory medicines, acute allergic reactions may be more likely to occur in patients who have exhibited allergic reactions to these compounds.
Angioedema, oedema of the larynx, Stevens-Johnson syndrome, Lyell's syndrome (toxic epidermal necrolysis), erythema multiforme, perspiration, urticaria, rash and facial oedema may occur. Occurrence of rash is a definite reason for stopping medication because exfoliative dermatitis has been reported on continued use after development of a rash.
Renal failure, allergic glomerulonephritis, papillary necrosis, dysuria and hyponatremia have occurred. There have been reports of acute interstitial nephritis with haematuria, proteinuria, and occasionally nephrotic syndrome.
Drug Interactions:
Patients receiving an anticoagulant drug concurrently with Ponstan have had a prolongation of prothrombin time. Ponstan is contraindicated for patients taking an anticoagulant drug if careful and continuous monitoring of the levels of prothrombin and Factors VII, IX and X is not available.
Patients receiving lithium concurrently with NSAIDs, including Ponstan, have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance. Thus, when Ponstan and lithium are administered concurrently, patients should be observed carefully for signs of lithium toxicity.
Precautions:
Caution should be exercised in the administration of Ponstan to patients suffering from dehydration and/or renal disease, particularly the elderly.
Bronchoconstriction may occur with mefenamic acid in asthmatic patients with aspirin sensitivity.
Mefenamic acid and its metabolites may give a false positive reaction to certain urine tests for the presence of bile.
Toxicity has also been seen in patients with prerenal condition leading to a reduction in renal blood flow or blood volume. Patients at greatest risk are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics, and the elderly.